Depepsit Met 100 mg + 1000 mg Tabletki o zmodyfikowanym uwalnianiu Polandia - Polski - URPL (Urząd Rejestracji Produktów Leczniczych, Wyrobów Medycznych i Produktów Biobójczych)

depepsit met 100 mg + 1000 mg tabletki o zmodyfikowanym uwalnianiu

adamed pharma s.a. - sitagliptin hydrochloride monohydrate + metformini hydrochloridum - tabletki o zmodyfikowanym uwalnianiu - 100 mg + 1000 mg

Depepsit Met 50 mg + 1000 mg Tabletki o zmodyfikowanym uwalnianiu Polandia - Polski - URPL (Urząd Rejestracji Produktów Leczniczych, Wyrobów Medycznych i Produktów Biobójczych)

depepsit met 50 mg + 1000 mg tabletki o zmodyfikowanym uwalnianiu

adamed pharma s.a. - sitagliptin hydrochloride monohydrate + metformini hydrochloridum - tabletki o zmodyfikowanym uwalnianiu - 50 mg + 1000 mg

Depepsit Met 50 mg + 500 mg Tabletki o zmodyfikowanym uwalnianiu Polandia - Polski - URPL (Urząd Rejestracji Produktów Leczniczych, Wyrobów Medycznych i Produktów Biobójczych)

depepsit met 50 mg + 500 mg tabletki o zmodyfikowanym uwalnianiu

adamed pharma s.a. - sitagliptin hydrochloride monohydrate + metformini hydrochloridum - tabletki o zmodyfikowanym uwalnianiu - 50 mg + 500 mg

Sitagliptin + Metformin hydrochloride APC 100 mg + 1000 mg Tabletki o zmodyfikowanym uwalnianiu Polandia - Polski - URPL (Urząd Rejestracji Produktów Leczniczych, Wyrobów Medycznych i Produktów Biobójczych)

sitagliptin + metformin hydrochloride apc 100 mg + 1000 mg tabletki o zmodyfikowanym uwalnianiu

apc instytut sp. z o.o. - sitagliptin hydrochloride monohydrate + metformini hydrochloridum - tabletki o zmodyfikowanym uwalnianiu - 100 mg + 1000 mg

Sitagliptin + Metformin hydrochloride APC 50 mg + 500 mg Tabletki o zmodyfikowanym uwalnianiu Polandia - Polski - URPL (Urząd Rejestracji Produktów Leczniczych, Wyrobów Medycznych i Produktów Biobójczych)

sitagliptin + metformin hydrochloride apc 50 mg + 500 mg tabletki o zmodyfikowanym uwalnianiu

apc instytut sp. z o.o. - sitagliptin hydrochloride monohydrate + metformini hydrochloridum - tabletki o zmodyfikowanym uwalnianiu - 50 mg + 500 mg

Sitagliptin + Metformin hydrochloride APC 50 mg + 1000 mg Tabletki o zmodyfikowanym uwalnianiu Polandia - Polski - URPL (Urząd Rejestracji Produktów Leczniczych, Wyrobów Medycznych i Produktów Biobójczych)

sitagliptin + metformin hydrochloride apc 50 mg + 1000 mg tabletki o zmodyfikowanym uwalnianiu

apc instytut sp. z o.o. - sitagliptin hydrochloride monohydrate + metformini hydrochloridum - tabletki o zmodyfikowanym uwalnianiu - 50 mg + 1000 mg

Prezista Uni Eropa - Polski - EMA (European Medicines Agency)

prezista

janssen-cilag international nv - darunawir - infekcje hiv - Środki przeciwwirusowe do użytku ogólnoustrojowego - prezista, co administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (hiv 1) infection in adult and paediatric patients from the age of 3 years and at least 15 kg body weight. prezista, co administered with cobicistat is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (hiv 1) infection in adults and adolescents (aged 12 years and older, weighing at least 40 kg). in deciding to initiate treatment with prezista co administered with cobicistat or low dose ritonavir, careful consideration should be given to the treatment history of the individual patient and the patterns of mutations associated with different agents. genotypic or phenotypic testing (when available) and treatment history should guide the use of prezista. prezista, co administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of patients with human immunodeficiency virus (hiv 1) infection. prezista 75 mg, 150 mg, and 600 mg tablets may be used to provide suitable dose regimens:for the treatment of hiv 1 infection in antiretroviral treatment (art) experienced adult patients, including those that have been highly pre treated. for the treatment of hiv 1 infection in paediatric patients from the age of 3 years and at least 15 kg body weight. in deciding to initiate treatment with prezista co administered with low dose ritonavir, careful consideration should be given to the treatment history of the individual patient and the patterns of mutations associated with different agents. genotypic or phenotypic testing (when available) and treatment history should guide the use of prezista. prezista, co administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of patients with human immunodeficiency virus (hiv 1) infection. prezista, co administered with cobicistat is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (hiv 1) infection in adults and adolescents (aged 12 years and older, weighing at least 40 kg). prezista 400 mg and 800 mg tablets may be used to provide suitable dose regimens for the treatment of hiv 1 infection in adult and paediatric patients from the age of 3 years and at least 40 kg body weight who are:antiretroviral therapy (art) naïve. art experienced with no darunavir resistance associated mutations (drv rams) and who have plasma hiv 1 rna < 100,000 copies/ml and cd4+ cell count ≥ 100 cells x 106/l. in deciding to initiate treatment with prezista in such art experienced patients, genotypic testing should guide the use of prezista.

Emtricitabine/Tenofovir disoproxil Mylan Uni Eropa - Polski - EMA (European Medicines Agency)

emtricitabine/tenofovir disoproxil mylan

mylan pharmaceuticals limited - эмтрицитабин, tenofowir disoproxil tymololu - infekcje hiv - Środki przeciwwirusowe do użytku ogólnoustrojowego - treatment of hiv-1 infection:emtricitabine/tenofovir disoproxil mylan is indicated in antiretroviral combination therapy for the treatment of hiv-1 infected adults (see section 5. emtricitabine/tenofovir disoproxil mylan is also indicated for the treatment of hiv-1 infected adolescents, with nrti resistance or toxicities precluding the use of first line agents, (see sections 4. 2, 4. 4 i 5. pre-exposure prophylaxis (prep):emtricitabine/tenofovir disoproxil mylan is indicated in combination with safer sex practices for pre-exposure prophylaxis to reduce the risk of sexually acquired hiv-1 infection in adults and adolescents at high risk (see sections 4. 2, 4. 4 i 5.

Triumeq Uni Eropa - Polski - EMA (European Medicines Agency)

triumeq

viiv healthcare b.v. - dolutegravir sodium, lamivudine, abacavir (as sulfate) - infekcje hiv - Środki przeciwwirusowe do użytku ogólnoustrojowego - triumeq is indicated for the treatment of human immunodeficiency virus (hiv) infected adults,  adolescents and children  weighing at least 25 kg who are antiretroviral treatment-naïve or are infected with hiv without documented or clinically suspected resistance to any of the three antiretroviral agents in triumeq.